was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25
minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your childs health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.
About Akili
Akili is pioneering the development of
cognitive treatments through game-changing technologies. Akilis approach of leveraging technologies designed to directly target the brain establishes a new category of medicine medicine that is validated through clinical trials like a
drug or medical device, but experienced like entertainment. Akilis platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through
rigorous clinical programs. Driven by Akilis belief that effective medicine can also be fun and engaging, Akilis products are delivered through captivating action video game experiences. For more information, please visit
www.akiliinteractive.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These
forward-looking statements generally are identified by the words believe, project, expect, anticipate, estimate, intend, strategy, future,
opportunity, plan, prepare, pursue, may, should, will, would, will be, will continue, will likely result, and similar
expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking
statements include, without limitation, statements in this press release related to: our expectations regarding the number of pediatric patients with ADHD who can now access EndeavorRx and our ability to expand the use of EndeavorRx in those
patients in connection with the label expansion for EndeavorRx to include adolescents ages 13 to 17 with ADHD; that the adoption and efficacy of EndeavorRx in patients aged 13 to 17 with ADHD will be similar to younger patients; and that the results
of our clinical studies are predictive of future clinical trials or results. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: our
ability to continue to commercialize EndeavorRx in patients aged 13 to 17; our ability to obtain regulatory clearance from FDA to convert our products to
over-the-counter-labeling; our ability to successfully create, and navigate, a new category of medicine and to achieve broad adoption of digital therapeutics among
customers and healthcare providers; our ability to continue to advance our clinical development pipeline; our ability to defend our intellectual property and satisfy various FDA and other regulatory requirements in and outside of the United States;
the risk of adverse